...thymalfasin to treat HBV and HCV infection, certain cancers and as a vaccine adjuvant, and DC Bead...

...to treat chronic HCV genotype 1 infection BTG plc (LSE:BTG)/SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) China approves DC Bead...

...approved BTG's DC Bead to treat patients with malignant hypervascularized tumors, such as hepatocellular carcinoma (HCC). DC Bead...
...2011. BTG plc (LSE:BTG), London, U.K. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: DC Bead ( E7040...

...CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead...

...CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead...

...Eisai launched DC Bead in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients...
...treatment materials (STM) category for medical device reimbursement under the Japan's National Health Insurance system. DC Bead...

...Eisai disclosed in its 1Q13 earnings that DC Bead was approved in Japan as a device for...
...as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). DC Bead...
...Tokyo:4523; Osaka:4523), Tokyo, Japan Product: DC Bead ( LC Bead , Embolic Bead E7040 ) ( Paragon Bead ) (E7040...

...March 31, 2013. Revenues were £36.1 million ($54.8 million) for BTG's interventional medicines, which includes LC Bead...

...has rights to DC Bead from Biocompatibles International plc , which BTG acquired in January 2011. DC Bead...
...London, U.K. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: DC Bead , Paragon Bead ( E7040...

...drive significant outperformance." She expects data "imminently" from the Phase II SPACE trial of BTG's DC Bead...
...treat varicose veins and a Phase IIb trial of CytoFab for severe sepsis. BTG markets DC Bead...